BioNxt Solutions Inc. (CVE:BNXT) | WebDisclosure

Basculer en Français

9475	Companies
185452	Keywords
117793	Articles
99303	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

PRESS RELEASE

published on 10/09/2025 at 09:05, 1 month 27 days ago

BioNxt Completes "Fast-Track" US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis
BioNxt Solutions Inc. completes Track One priority patent filing with USPTO for sublingual thin-film cladribine formulation (BNT23001) targeting MS & other autoimmune diseases. Strategic move to strengthen IP position & advance regulatory approvals

BioNxt Solutions Inc. Multiple Sclerosis Patent Filing Sublingual Thin-Film Cladribine Formulation
BRIEF

published on 10/02/2025 at 09:10, 2 months 3 days ago

BioNxt développe une plateforme d'administration ciblée de médicaments de chimiothérapie

Biopharmaceutique Solutions BioNxt Administration De Médicaments Chimiothérapie Ciblée Avancées De La Recherche
BRIEF

published on 10/02/2025 at 09:10, 2 months 3 days ago

BioNxt Advances Targeted Chemotherapy Drug Delivery Platform

Biopharmaceutical Drug Delivery Research Advancements BioNxt Solutions Targeted Chemotherapy
PRESS RELEASE

published on 10/02/2025 at 09:05, 2 months 3 days ago

BioNxt Reports Update on Targeted Chemotherapy Drug Delivery Platform
BioNxt Solutions Inc. reports significant advancement in targeted chemotherapy delivery platform and upcoming definitive agreement. Proprietary technology aims at 10-fold increase in therapeutic effect while safeguarding healthy cells

BioNxt Solutions Inc. Oncology Treatments Chemotherapy Delivery Platform Targeted Drug Delivery System Therapeutic Effect
BRIEF

published on 09/29/2025 at 09:10, 2 months 6 days ago

BioNxt Advances Cladribine Sublingual Drug Development for Multiple Sclerosis

Drug Development Multiple Sclerosis Cladribine Bioavailability Sublingual
BRIEF

published on 09/29/2025 at 09:10, 2 months 6 days ago

BioNxt fait progresser le développement d'un médicament sublingual à base de cladribine pour le traitement de la sclérose en plaques

Sclérose En Plaques Cladribine Développement De Médicaments Biodisponibilité Sublingual
PRESS RELEASE

published on 09/29/2025 at 09:05, 2 months 6 days ago

BioNxt Reports Sublingual Cladribine Multiple Sclerosis Drug Milestones Including Large-Animal Study for Validation and Dosing Optimization
BioNxt Solutions provides update on Cladribine sublingual thin-film drug reformulation program, targeting treatment of multiple sclerosis with improved bioavailability and patient adherence

Multiple Sclerosis Cladribine Neurological Disorders BioNxt Solutions Drug Delivery Technologies
BRIEF

published on 09/20/2025 at 03:50, 2 months 15 days ago

BioNxt Solutions Completes Shares for Debt Settlement

Common Shares Debt Settlement Debt Agreement Canadian Securities BioNxt Solutions
BRIEF

published on 09/20/2025 at 03:50, 2 months 15 days ago

BioNxt Solutions lève des actions pour régler sa dette

Actions Ordinaires Règlement De La Dette Solutions BioNxt Valeurs Mobilières Canadiennes Accord De Dette
PRESS RELEASE

published on 09/20/2025 at 03:45, 2 months 15 days ago

BioNxt Solutions Announces Closing of Shares for Debt Settlement
BioNxt Solutions Inc. announces successful debt settlement with creditor, issuing common shares and making cash payment. Company focuses on bioscience innovation and drug delivery technologies

Common Shares Debt Settlement BioNxt Solutions Inc. Drug Delivery Technologies Bioscience Innovation

Accesswire

Published on 12/05/2025 at 02:35, 10 hours 45 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 10 hours 50 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 12 hours 20 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 14 hours 15 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 14 hours 20 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 13:00, 20 minutes ago

Zentra Group plc: Posting of Notice of Annual General Meeting
Published on 12/05/2025 at 13:00, 20 minutes ago

Form 8.3 - Zürcher Kantonalbank: Cicor Technologies Ltd.
Published on 12/05/2025 at 12:05, 1 hour 14 minutes ago

Cango Inc. Announces November 2025 Bitcoin Production and Mining Operations Update
Published on 12/05/2025 at 12:00, 1 hour 20 minutes ago

CGTN：Strengthening cultural ties: Peng Liyuan, Brigitte Macron visit Beijing People's Art Theatre
Published on 12/05/2025 at 12:00, 1 hour 20 minutes ago

Iute Group: Successful Issue of Additional EUR 2025/2030 Bonds – Circulating Volume Increased to EUR 160 Million

Les Echos

Published on 12/05/2025 at 08:45, 4 hours 35 minutes ago

Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 4 hours 35 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/05/2025 at 08:42, 4 hours 37 minutes ago

ENGIE - déclaration mensuelle du nombre total d'actions et de droits de vote composant le capital au 30 novembre 2025
Published on 12/04/2025 at 18:14, 19 hours 5 minutes ago

Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 19 hours 20 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025

View all LES ECHOS COMFI WIRE